Clinical Trials Browser

Phase 3 × CPX-351 × 90 days × Clear all

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute